Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
Kiromic BioPharma, Inc. (KRBP)
Company Research
Source: Business Wire
Recent Corporate Highlights Include:New Leadership Appointed at the Company, Board of Director LevelCompleted Studies to Further Optimize Potency and Validity of the ALEXIS Gamma Delta T (GDT) Cell PlatformProgressed a Master Cell Bank Strategy for Retro-viral Vector (RVV) ProductionEnhanced Kiromic’s Diamond AI™ Mediated Pooled Donor Gamma Delta T Cell Banking TechnologyExpansion and Redesign of In-house cGMP Manufacturing FacilityDIAMOND®AI 2.0 New Component NOEMI (NeurO Evolutive) Machine Learning Enabled Antibody Design) Designed to Dramatically Reduce Time and Cost of CAR-T Cell Therapy DevelopmentCash Position $15,123,100 as of March 31, 2022 HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today an
Show less
Read more
Impact Snapshot
Event Time:
KRBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRBP alerts
High impacting Kiromic BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
KRBP
News
- Kiromic BioPharma on plans to submit revised clinical trial application [Seeking Alpha]Seeking Alpha
- Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022Business Wire
- Kiromic BioPharma Announces Availability of Company’s Current Corporate PresentationBusiness Wire
- Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate HighlightsBusiness Wire
- HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Kiromic BioPharma, Inc. (KRBP) with Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law ViolationsGlobeNewswire
KRBP
Earnings
- 5/13/22 - Miss
KRBP
Sec Filings
- 5/13/22 - Form 10-Q
- 5/13/22 - Form 8-K
- 5/11/22 - Form 8-K
- KRBP's page on the SEC website